A research team led by Douglas Graham has developed a fusion protein for the inhibition of Axl to be used as a therapeutic for certain cancers and thrombosis. This was accomplished by fusing the extracellular domain of Axl to a fusion partner (an Fc region of an immunoglobulin). The fusion protein then inhibits the overexpression and proliferation of Axl by binding to and sequestering ligands. Inventors have demonstrated the efficacy of this method on a cell line of non small cell lung cancer (NSCLC). Results showed the Axl-Fc fusion protein worked to inhibit colony formation in NSCLC. Axl inhibition could increase remission and survival rate for cancers including lung cancer, myeloid leukemia, uterine cancer, ovarian cancer, gliomas, melanoma, prostate cancer, breast cancer, gastric cancer, osteosarcoma, renal cell carcinoma, and thyroid cancer. Axl fusion also decreases platelet aggregation in response to collagen and can thus be used as an anti-thrombotic therapy as well.